Nureca Ltd. (IN:NURECA)
:NURECA
Want to see IN:NURECA full AI Analyst Report?
NURECA Stock Chart & Stats
₹298.85
-₹10.75(-3.41%)
At close: 4:00 PM EST
₹298.85
-₹10.75(-3.41%)
Day’s Range― - ―
52-Week Range₹200.10 - ₹343.60
Previous CloseN/A
Volume68.50K
Average Volume (3M)9.27K
Market Cap
₹2.27B
Enterprise Value₹2.86B
Total Cash (Recent Filing)₹87.40M
Total Debt (Recent Filing)₹53.92M
Price to Earnings (P/E)107.6
Beta1.11
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.11
Shares Outstanding9,541,920
10 Day Avg. Volume526
30 Day Avg. Volume9,266
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)1.13
Price to Sales (P/S)1.39
P/FCF Ratio116.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA conservatively financed balance sheet with debt-to-equity near 1.2% provides durable financial flexibility. Over a 2–6 month horizon this reduces bankruptcy and refinancing risk, supporting capex or working capital needs and enabling strategic responses to market or supply shocks.
Revenue Recovery & ProfitabilityImproved top-line momentum (~13% FY2026) and a return to positive profitability indicate the business can regain volume and control costs after prior declines. This recovery suggests structural demand elasticity and operational improvements that can sustain earnings over the medium term.
Favorable End-market PositioningPositioning in home healthcare and wellness aligns with long-term structural trends toward at‑home care and self-monitoring. That durable secular demand supports recurring consumable sales, cross‑sell potential, and resilience to episodic disruptions in institutional channels over months.
Bears Say
Thin MarginsPersistently thin operating and net margins constrain internal cash generation and signal weak pricing power or a low‑value product mix. Over several months this limits reinvestment capacity, raises sensitivity to input cost inflation, and requires materially better unit economics to improve returns.
Weak Cash ConversionVolatile and weak conversion of profit to free cash flow creates execution risk: working capital swings and past cash burn reduce the reliability of internally funded growth. This elevates dependence on external financing for sustained expansion or margin recovery.
Low Returns On Capital / Earnings VolatilityVery low ROE alongside historical revenue swings implies the company is not efficiently converting its equity base into durable profits. Over a medium horizon this limits shareholder value creation absent structural margin improvement or higher asset turnover.
Nureca Ltd. News
NURECA FAQ
What was Nureca Ltd.’s price range in the past 12 months?
Nureca Ltd. lowest stock price was ₹200.10 and its highest was ₹343.60 in the past 12 months.
What is Nureca Ltd.’s market cap?
Nureca Ltd.’s market cap is ₹2.27B.
When is Nureca Ltd.’s upcoming earnings report date?
Nureca Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Nureca Ltd.’s earnings last quarter?
Nureca Ltd. released its earnings results on May 29, 2026. The company reported -₹6.45 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.45.
Is Nureca Ltd. overvalued?
According to Wall Street analysts Nureca Ltd.’s price is currently Overvalued.
Does Nureca Ltd. pay dividends?
Nureca Ltd. pays a Semiannually dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Nureca Ltd. dividends here
What is Nureca Ltd.’s EPS estimate?
Nureca Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nureca Ltd. have?
Nureca Ltd. has 9,541,920 shares outstanding.
What happened to Nureca Ltd.’s price movement after its last earnings report?
Nureca Ltd. reported an EPS of -₹6.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.775%.
Which hedge fund is a major shareholder of Nureca Ltd.?
Currently, no hedge funds are holding shares in IN:NURECA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nureca Ltd.
Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthopedic products, including massagers, pain monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise, fitness tracking, and dental and personal care products. The company also provides mother and baby care products comprising baby feeding, carry cots, baby skincare, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG, fitness tracker, and smart weighing scale products. Nureca Limited offers its products under Dr Trust, Dr Physio, and Trumom brands. The company sells its products through third party e-commerce players, distributors, and retailers; and through its website, drtrust.in. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
Technical Analysis
Amrutanjan Health Care Limited
―
Blue Jet Healthcare Limited
―
Procter & Gamble Health Ltd.
―
Sanofi Consumer Healthcare India Limited
―
Zota Health Care Ltd.
―